nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP3A4—Vandetanib—thyroid cancer	0.109	0.286	CbGbCtD
Vilazodone—CYP2D6—Sorafenib—thyroid cancer	0.104	0.271	CbGbCtD
Vilazodone—CYP3A4—Sorafenib—thyroid cancer	0.0659	0.173	CbGbCtD
Vilazodone—CYP2D6—Doxorubicin—thyroid cancer	0.0628	0.165	CbGbCtD
Vilazodone—CYP3A4—Doxorubicin—thyroid cancer	0.04	0.105	CbGbCtD
Vilazodone—Suicide—Sorafenib—thyroid cancer	0.0271	0.0439	CcSEcCtD
Vilazodone—Completed suicide—Sorafenib—thyroid cancer	0.0239	0.0387	CcSEcCtD
Vilazodone—Cataract—Vandetanib—thyroid cancer	0.0219	0.0355	CcSEcCtD
Vilazodone—Dry eye—Vandetanib—thyroid cancer	0.0193	0.0312	CcSEcCtD
Vilazodone—Gastroenteritis—Vandetanib—thyroid cancer	0.0171	0.0276	CcSEcCtD
Vilazodone—Hyponatraemia—Vandetanib—thyroid cancer	0.0152	0.0246	CcSEcCtD
Vilazodone—Pollakiuria—Vandetanib—thyroid cancer	0.0121	0.0196	CcSEcCtD
Vilazodone—Hyponatraemia—Sorafenib—thyroid cancer	0.0103	0.0166	CcSEcCtD
Vilazodone—Eye disorder—Vandetanib—thyroid cancer	0.0098	0.0158	CcSEcCtD
Vilazodone—Cardiac disorder—Vandetanib—thyroid cancer	0.00973	0.0157	CcSEcCtD
Vilazodone—Breast disorder—Sorafenib—thyroid cancer	0.00924	0.0149	CcSEcCtD
Vilazodone—Mental disorder—Vandetanib—thyroid cancer	0.00918	0.0149	CcSEcCtD
Vilazodone—Malnutrition—Vandetanib—thyroid cancer	0.00913	0.0148	CcSEcCtD
Vilazodone—Dysgeusia—Vandetanib—thyroid cancer	0.00894	0.0145	CcSEcCtD
Vilazodone—Vision blurred—Vandetanib—thyroid cancer	0.0086	0.0139	CcSEcCtD
Vilazodone—Tremor—Vandetanib—thyroid cancer	0.00855	0.0138	CcSEcCtD
Vilazodone—Erectile dysfunction—Sorafenib—thyroid cancer	0.00814	0.0132	CcSEcCtD
Vilazodone—Convulsion—Vandetanib—thyroid cancer	0.00791	0.0128	CcSEcCtD
Vilazodone—Arthralgia—Vandetanib—thyroid cancer	0.00777	0.0126	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00772	0.0125	CcSEcCtD
Vilazodone—Dry mouth—Vandetanib—thyroid cancer	0.0076	0.0123	CcSEcCtD
Vilazodone—Nervous system disorder—Vandetanib—thyroid cancer	0.0073	0.0118	CcSEcCtD
Vilazodone—Skin disorder—Vandetanib—thyroid cancer	0.00723	0.0117	CcSEcCtD
Vilazodone—Connective tissue disorder—Sorafenib—thyroid cancer	0.00695	0.0112	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00679	0.011	CcSEcCtD
Vilazodone—Insomnia—Vandetanib—thyroid cancer	0.00674	0.0109	CcSEcCtD
Vilazodone—Paraesthesia—Vandetanib—thyroid cancer	0.00669	0.0108	CcSEcCtD
Vilazodone—Cardiac disorder—Sorafenib—thyroid cancer	0.00656	0.0106	CcSEcCtD
Vilazodone—Dyspepsia—Vandetanib—thyroid cancer	0.00656	0.0106	CcSEcCtD
Vilazodone—Decreased appetite—Vandetanib—thyroid cancer	0.00647	0.0105	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00643	0.0104	CcSEcCtD
Vilazodone—Fatigue—Vandetanib—thyroid cancer	0.00642	0.0104	CcSEcCtD
Vilazodone—Mental disorder—Sorafenib—thyroid cancer	0.0062	0.01	CcSEcCtD
Vilazodone—Malnutrition—Sorafenib—thyroid cancer	0.00616	0.00995	CcSEcCtD
Vilazodone—Dysgeusia—Sorafenib—thyroid cancer	0.00603	0.00975	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Epirubicin—thyroid cancer	0.00576	0.00932	CcSEcCtD
Vilazodone—Asthenia—Vandetanib—thyroid cancer	0.00534	0.00864	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Doxorubicin—thyroid cancer	0.00533	0.00862	CcSEcCtD
Vilazodone—Arthralgia—Sorafenib—thyroid cancer	0.00524	0.00847	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0052	0.00842	CcSEcCtD
Vilazodone—Abnormal dreams—Epirubicin—thyroid cancer	0.00514	0.00832	CcSEcCtD
Vilazodone—Dry mouth—Sorafenib—thyroid cancer	0.00513	0.00829	CcSEcCtD
Vilazodone—Diarrhoea—Vandetanib—thyroid cancer	0.0051	0.00824	CcSEcCtD
Vilazodone—Nervous system disorder—Sorafenib—thyroid cancer	0.00493	0.00797	CcSEcCtD
Vilazodone—Dizziness—Vandetanib—thyroid cancer	0.00493	0.00796	CcSEcCtD
Vilazodone—Skin disorder—Sorafenib—thyroid cancer	0.00488	0.00789	CcSEcCtD
Vilazodone—Dry eye—Epirubicin—thyroid cancer	0.00481	0.00777	CcSEcCtD
Vilazodone—Abnormal dreams—Doxorubicin—thyroid cancer	0.00476	0.0077	CcSEcCtD
Vilazodone—Vomiting—Vandetanib—thyroid cancer	0.00474	0.00766	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00458	0.0074	CcSEcCtD
Vilazodone—Dry eye—Doxorubicin—thyroid cancer	0.00445	0.00719	CcSEcCtD
Vilazodone—Nausea—Vandetanib—thyroid cancer	0.00442	0.00715	CcSEcCtD
Vilazodone—Dyspepsia—Sorafenib—thyroid cancer	0.00442	0.00715	CcSEcCtD
Vilazodone—Decreased appetite—Sorafenib—thyroid cancer	0.00437	0.00706	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00434	0.00701	CcSEcCtD
Vilazodone—Fatigue—Sorafenib—thyroid cancer	0.00433	0.007	CcSEcCtD
Vilazodone—Increased appetite—Epirubicin—thyroid cancer	0.00402	0.0065	CcSEcCtD
Vilazodone—Hyponatraemia—Epirubicin—thyroid cancer	0.00379	0.00613	CcSEcCtD
Vilazodone—Increased appetite—Doxorubicin—thyroid cancer	0.00372	0.00602	CcSEcCtD
Vilazodone—Migraine—Epirubicin—thyroid cancer	0.00372	0.00601	CcSEcCtD
Vilazodone—Asthenia—Sorafenib—thyroid cancer	0.0036	0.00583	CcSEcCtD
Vilazodone—Hyponatraemia—Doxorubicin—thyroid cancer	0.00351	0.00567	CcSEcCtD
Vilazodone—Migraine—Doxorubicin—thyroid cancer	0.00344	0.00556	CcSEcCtD
Vilazodone—Diarrhoea—Sorafenib—thyroid cancer	0.00344	0.00556	CcSEcCtD
Vilazodone—Breast disorder—Epirubicin—thyroid cancer	0.00341	0.00552	CcSEcCtD
Vilazodone—Dizziness—Sorafenib—thyroid cancer	0.00332	0.00537	CcSEcCtD
Vilazodone—Vomiting—Sorafenib—thyroid cancer	0.00319	0.00517	CcSEcCtD
Vilazodone—Breast disorder—Doxorubicin—thyroid cancer	0.00316	0.00511	CcSEcCtD
Vilazodone—Pollakiuria—Epirubicin—thyroid cancer	0.00302	0.00488	CcSEcCtD
Vilazodone—Nausea—Sorafenib—thyroid cancer	0.00298	0.00483	CcSEcCtD
Vilazodone—Pollakiuria—Doxorubicin—thyroid cancer	0.00279	0.00451	CcSEcCtD
Vilazodone—Connective tissue disorder—Epirubicin—thyroid cancer	0.00257	0.00415	CcSEcCtD
Vilazodone—Eye disorder—Epirubicin—thyroid cancer	0.00244	0.00395	CcSEcCtD
Vilazodone—Cardiac disorder—Epirubicin—thyroid cancer	0.00243	0.00392	CcSEcCtD
Vilazodone—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00238	0.00384	CcSEcCtD
Vilazodone—Mental disorder—Epirubicin—thyroid cancer	0.00229	0.0037	CcSEcCtD
Vilazodone—Malnutrition—Epirubicin—thyroid cancer	0.00228	0.00368	CcSEcCtD
Vilazodone—Eye disorder—Doxorubicin—thyroid cancer	0.00226	0.00365	CcSEcCtD
Vilazodone—Cardiac disorder—Doxorubicin—thyroid cancer	0.00224	0.00363	CcSEcCtD
Vilazodone—Flatulence—Epirubicin—thyroid cancer	0.00224	0.00362	CcSEcCtD
Vilazodone—Dysgeusia—Epirubicin—thyroid cancer	0.00223	0.0036	CcSEcCtD
Vilazodone—Nervousness—Epirubicin—thyroid cancer	0.00221	0.00357	CcSEcCtD
Vilazodone—Vision blurred—Epirubicin—thyroid cancer	0.00214	0.00347	CcSEcCtD
Vilazodone—Mental disorder—Doxorubicin—thyroid cancer	0.00212	0.00343	CcSEcCtD
Vilazodone—Malnutrition—Doxorubicin—thyroid cancer	0.00211	0.0034	CcSEcCtD
Vilazodone—Agitation—Epirubicin—thyroid cancer	0.00209	0.00338	CcSEcCtD
Vilazodone—Flatulence—Doxorubicin—thyroid cancer	0.00207	0.00335	CcSEcCtD
Vilazodone—Dysgeusia—Doxorubicin—thyroid cancer	0.00206	0.00333	CcSEcCtD
Vilazodone—Nervousness—Doxorubicin—thyroid cancer	0.00204	0.00331	CcSEcCtD
Vilazodone—Palpitations—Epirubicin—thyroid cancer	0.00201	0.00325	CcSEcCtD
Vilazodone—Vision blurred—Doxorubicin—thyroid cancer	0.00198	0.00321	CcSEcCtD
Vilazodone—Convulsion—Epirubicin—thyroid cancer	0.00197	0.00319	CcSEcCtD
Vilazodone—Arthralgia—Epirubicin—thyroid cancer	0.00194	0.00313	CcSEcCtD
Vilazodone—Agitation—Doxorubicin—thyroid cancer	0.00193	0.00313	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00192	0.00311	CcSEcCtD
Vilazodone—Dry mouth—Epirubicin—thyroid cancer	0.00189	0.00306	CcSEcCtD
Vilazodone—Palpitations—Doxorubicin—thyroid cancer	0.00186	0.00301	CcSEcCtD
Vilazodone—Convulsion—Doxorubicin—thyroid cancer	0.00182	0.00295	CcSEcCtD
Vilazodone—Nervous system disorder—Epirubicin—thyroid cancer	0.00182	0.00294	CcSEcCtD
Vilazodone—Skin disorder—Epirubicin—thyroid cancer	0.0018	0.00292	CcSEcCtD
Vilazodone—Hyperhidrosis—Epirubicin—thyroid cancer	0.00179	0.0029	CcSEcCtD
Vilazodone—Arthralgia—Doxorubicin—thyroid cancer	0.00179	0.0029	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00178	0.00288	CcSEcCtD
Vilazodone—Dry mouth—Doxorubicin—thyroid cancer	0.00175	0.00283	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00169	0.00274	CcSEcCtD
Vilazodone—Nervous system disorder—Doxorubicin—thyroid cancer	0.00168	0.00272	CcSEcCtD
Vilazodone—Insomnia—Epirubicin—thyroid cancer	0.00168	0.00272	CcSEcCtD
Vilazodone—Skin disorder—Doxorubicin—thyroid cancer	0.00167	0.0027	CcSEcCtD
Vilazodone—Paraesthesia—Epirubicin—thyroid cancer	0.00167	0.0027	CcSEcCtD
Vilazodone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00166	0.00269	CcSEcCtD
Vilazodone—Somnolence—Epirubicin—thyroid cancer	0.00165	0.00267	CcSEcCtD
Vilazodone—Dyspepsia—Epirubicin—thyroid cancer	0.00163	0.00264	CcSEcCtD
Vilazodone—Decreased appetite—Epirubicin—thyroid cancer	0.00161	0.00261	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.0016	0.00259	CcSEcCtD
Vilazodone—Fatigue—Epirubicin—thyroid cancer	0.0016	0.00259	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00157	0.00253	CcSEcCtD
Vilazodone—Insomnia—Doxorubicin—thyroid cancer	0.00155	0.00251	CcSEcCtD
Vilazodone—Paraesthesia—Doxorubicin—thyroid cancer	0.00154	0.00249	CcSEcCtD
Vilazodone—Feeling abnormal—Epirubicin—thyroid cancer	0.00153	0.00247	CcSEcCtD
Vilazodone—Somnolence—Doxorubicin—thyroid cancer	0.00153	0.00247	CcSEcCtD
Vilazodone—Dyspepsia—Doxorubicin—thyroid cancer	0.00151	0.00245	CcSEcCtD
Vilazodone—Decreased appetite—Doxorubicin—thyroid cancer	0.00149	0.00241	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00148	0.0024	CcSEcCtD
Vilazodone—Fatigue—Doxorubicin—thyroid cancer	0.00148	0.0024	CcSEcCtD
Vilazodone—Feeling abnormal—Doxorubicin—thyroid cancer	0.00142	0.00229	CcSEcCtD
Vilazodone—Asthenia—Epirubicin—thyroid cancer	0.00133	0.00215	CcSEcCtD
Vilazodone—Diarrhoea—Epirubicin—thyroid cancer	0.00127	0.00205	CcSEcCtD
Vilazodone—Asthenia—Doxorubicin—thyroid cancer	0.00123	0.00199	CcSEcCtD
Vilazodone—Dizziness—Epirubicin—thyroid cancer	0.00123	0.00199	CcSEcCtD
Vilazodone—Vomiting—Epirubicin—thyroid cancer	0.00118	0.00191	CcSEcCtD
Vilazodone—Diarrhoea—Doxorubicin—thyroid cancer	0.00118	0.0019	CcSEcCtD
Vilazodone—Dizziness—Doxorubicin—thyroid cancer	0.00114	0.00184	CcSEcCtD
Vilazodone—Nausea—Epirubicin—thyroid cancer	0.0011	0.00178	CcSEcCtD
Vilazodone—Vomiting—Doxorubicin—thyroid cancer	0.00109	0.00177	CcSEcCtD
Vilazodone—Nausea—Doxorubicin—thyroid cancer	0.00102	0.00165	CcSEcCtD
